Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Intrathecal CD133+ Stem Cells in Cerebral Palsy
NCT01763255Phase 2Completed
- Sponsor
- Royan Institute
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD133+ bone marrow-derived stem cells in cerebral palsy (CP) (2 arms), sponsored by Royan Institute. Primary endpoints: Motor Dysfunction at 6 months, Sensory Dysfunction at 6 months and 2 more. Started Apr 2012; status: completed.
02
Drugs
CD133+ bone marrow-derived stem cells
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT01763255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763255.